INDIRECT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT
https://doi.org/10.15690/pf.v9i2.237
Abstract
The article is devoted to evaluating methods of the effectiveness of new drugs, allowing the doctor or the head of the hospital to make the right choice in favor of the application of a medical technology in their activities. The author considers the general issues of methodology for indirect comparison of medical technologies for a new method of synthesis of evidence in decision-making process. An example of its use: indirect comparison of the pegylated interferon to treat hepatitis C.
About the Authors
S. V. Goryajnov
N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
O. Yu. Rebrova
N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
References
1. Bucher H.C., Gordon H.G., Lauren E.G., Walter S.D. The results of direct and indirect treatment comparisons in metaanalysis of randomized controlled trials. J ClinEpidemiol. 1997; 50 (6): 683-91
2. Jansen J.P., Fleurence R., Devine B. et al. Interpreting indirect treatment comparisons and network metaanalysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices.Part 1.Value In Health. 2011; 14: 417-428.
3. Song F., Altman D.G., Glenny A.M. et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta analyses. BMJ.2003; 1: 326.
4. Hoaglin D.C., Hawkins N., Jansen J.P. et al. Conducting indirect-treatment-comparison and networkmetaanalysisstudies: report of the ISPOR task force on indirect treatment comparisons good research practices.Part 2.Value In Health. 2011; 14: 429-437.
5. Song F., Harvey I., Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J ClinEpidemiol. 2008; 61 (5): 455-463.
6. Rumi M.G., Agemo A., Prati G.M. et al. Randomized study of peginterferon-?2a plus ribavirin vspeginterferon-?2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010; 138: 108-115.
7. Ascione A., Luca M.D., Tartaglione M.T. et al. Peginterferonalfa-2a plus ribavirin ismore effective than peginterferonalfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010; 138: 116-122.
8. McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361 (6): 580-593.
9. Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358 (9286): 958-965.
10. Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. NEnglJMed. 2002; 347 (13): 975-982.
Review
For citations:
Goryajnov S.V., Rebrova O.Yu. INDIRECT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT. Pediatric pharmacology. 2012;9(2):6-9. https://doi.org/10.15690/pf.v9i2.237
Views:
748
Email this article 